Skip to Navigation Skip to Search Skip to Content
Search All Centers

Where Do We Stand with JAK Inhibitors in Development?

Read Transcript Download/Print Transcript
View next

Published on March 5, 2014

Are there additional JAK inhibitors in development? Dr. Claire Harrison, a leading MPN researcher, discusses JAK inhibitor drugs currently in clinical trials. Dr. Harrison reviews encouraging early data and explains what it could mean for patients.

Made possible through an educational grant from the Patient Empowerment Network.


Transcript | Where Do We Stand with JAK Inhibitors in Development?

But there are other JAK inhibitors which are available about which there are important information at this meeting.  None of these drugs have completed Phase III studies, unfortunately.  Fedratinib was at the point where it had completed Phase III study, was in the process of completing a study for patients as a second-line drug after ruxolitinib, showed promise, so it demonstrates there is a need, as you rightly say. 

So the other drugs that we see discussed at this meeting are pacritinib, SB1518.  There's nice data with Serge and others showing long?term data with this agent, showing again there is little gastrointestinal toxicity.  This might be a strong candidate drug for patients with lower blood counts and producing quite striking clinical benefit.  As you probably know, the PERSIST?1 study is ongoing with pacritinib. And PERSIST?2, which allows us to enroll patients who previously had a JAK inhibitor, will be opening shortly. 

Other drugs, momelotinib, previously known as CYT387, an update presented by colleagues from the Mayo Clinic again showing benefits for spleen symptoms and this intriguing story of anemia response.  And we've very much hope to be able to launch a Phase III study with that drug, which is likely it seems to be perhaps a head?to?head study with ruxolitinib.  I think this is very important and a very laudable approach for patients in particular, so we won't be saying, well, you can have this JAK inhibitor, or you can have a sugar pill, or you can have best available therapy, because frankly that's not ethical anymore.  So we will be comparing, I think, in the future likely at least first line these drugs against ruxolitinib.  So momelotinib, I think, is the one to watch. 

 The BMS drug, also interesting.  And the Lilly drug also presenting data at this meeting.  

Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, contributors, partners or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That’s how you’ll get care that’s most appropriate for you.


View next